Studies on the role of the NLRP3 inflammasome in DCM patients are scarce, let alone clinical trials of NLRP3 inflammasome inhibitors, indeed, with the exception of OLT117, which is currently being investigated in a phase I clinical trial for the treatment of heart failure. This evidence concerns the gene NLRP3 and familial dilated cardiomyopathy.